{"name":"Virion Therapeutics","slug":"virion-therapeutics","ticker":"","exchange":"","domain":"","description":"Virion Therapeutics is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company's pipeline includes two lead candidates, VRON-0200-AdC7 and VRON-0200-AdC6, both currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNd0JZSkFPMTdNLTF4RzU4V0xLTWxWM1E0SzdZX2JYejhfVWJDS0s1STBTQVRacnlxdl8wZTJPR181YzkwazlVRENDWElIcGhIdkJSSUFnUndsOTNLT3lSbzZSRHlDWUZTNEhKTXRvc3dSYmlkcVJNTGpOM01yaTFzRjY0Z3BwT3lsYkd5aW93T3g2bTJEZHo3ZHJjR1U3cUxMcVFScmZ3WTdHdWVYR3FMS0FzTmgzQ1R2M3JFSTVzWlZDMTE3ZUU0UngyMjhDZDFoeXhmdWZiZVZIM0NGZ0RWQmVGSGw1Uk5WYVVCTmdNRnhHcG1pVFE?oc=5","date":"2026-03-27","type":"pipeline","source":"Barchart.com","summary":"Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook - Barchart.com","headline":"Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Ou","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE90V3FOMEwyQkhsWHdUTk5UVlBBX1JoQU5GSWJORWxHaXF5dkFmSHBOSXFYYi1aS0dFcEQtenppNWc0LU0zOEp0YUpMT0gxSWV6ZXEzTmZGTkpLWDBHYUw4QkRJelVib0NpRXB2eGFCWC1yYlZsOFE?oc=5","date":"2026-02-28","type":"pipeline","source":"European AIDS Treatment Group","summary":"CROI 2026: Viral hepatitis highlights - European AIDS Treatment Group","headline":"CROI 2026: Viral hepatitis highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxPYXh2N3ZPVkJXR3FOdmVxOHYyOTY1NVhvb1hZSzA1MkVrRXJaR3hoTUxYaDNZUUJ1bGg2OFA1WTR3VG5yWXl1ZjV2Yjl1U2E0SFctdDUzY2N6RHNaNzl2NHEzMzFLNkdUemk5bmMtb19GamUyd1JPNHJfbkZ5TkZBMWluY0h3cHUxRHlLQkk2RVA2Wnp1UkpvWEl5YzlqWlRpNlFHU0JzRTZBRnBkVERabmRKcjV1djJBNTRJaDhoVlBwZ3NsUnNCaXBUM1pQYUZMMkhaZU9uMkdYTF9Wbl9RQzVRRlJPZk5QckxhSEVjWXJfb2ZuRXNzOXF2bGYtZ2RHZ1NYalM3Wl9iSEtEYXJwSlc3Ri1jbi03aVk3U0Y0eEJjV0pObTZ3RDR0LUt2VHM1dWxULXNoeGtVWmRwamtmeGFnU1hrUU1fY2ZiQkl3?oc=5","date":"2026-02-22","type":"trial","source":"BioSpace","summary":"Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026 - BioSpace","headline":"Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of C","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-09","type":"trial","source":"Business Wire","summary":"Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b Study at AASLD’s The Liver M","headline":"Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Y","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxPdVlfbW4wVVdVMmlIaWp3dVFLaF9hUnBDRk9NbVU4bHIxTVRxVlZtMmtCRFlvbzVFQkI0eVhSNm44dUhwOFNkSUVZSlZmNlJuZGpkLUVuTFZ2SWhtTGlXNGFmUHpPbW1HX0NHbER2TE9NcnQwbTljV1hhYjdBZ1liUUtMejhCYnhKcHhOMWRjelFtaWxSUVBDVlF3cmJDRkd0T0Q5QzNiUHFDdVZFV1pzYlpFckRVZEtDSVFKSHkwTkEwOGNOMTZaeUpvMGRJcGZTM2RlcVdON2xteFF3ZjVZZEVSbHpHOEF1QlFOeVo5MUVxYW9aZDN3eWM0TUlRSFNIcHo2Wm1oV2R0LVUzYXpVUllJMk1WSU5XQThuUWttampNNFlXSXBqWGRwazJUVFlSTktXb2JvcEJwd2QzZlA1cVl4dXYzRURyaGc?oc=5","date":"2025-10-07","type":"trial","source":"Business Wire","summary":"Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2025 - Business Wire","headline":"Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOdEZPQThPUWEyeVB2X1g4S1ExSS1faURVTE5jVkk5TWg4TVBQNVNZeGlvVGZZNmU5Y0V4MUc0MlNxZ3VadDJZM0tJOXV3REItMDFtc1BudG92ZmVQeVhnRFlVdVBoZUFzb0JmVEZudHZlZnYxMF9nbjgzSDJrTk9HTkJiS05ob0VlUGpMSEEyMVQxM2FWWUZnR0NSbVNIeHlvclhVYmQ0b2pDWF9CbDRLdlhkQWgzNml1M012VEdVdmZiU3Qwc29fMF96VVEzUDZLRTREbmZoVjlxUFJEOWVDMDRkYXZNYnNNQUk4N0JidXBYQkMxNmZnUlVYN3UzRDFSaWVXRGJyLW9KQXVyV2dtaGRBM1lGQ004Z3c?oc=5","date":"2025-01-10","type":"trial","source":"PR Newswire","summary":"Virion Therapeutics Completes Enrollment of First 2 Cohorts of Phase 1b Chronic Hepatitis B Trial of VRON-0200 For HBV Functional Cure - PR Newswire","headline":"Virion Therapeutics Completes Enrollment of First 2 Cohorts of Phase 1b Chronic Hepatitis B Trial of VRON-0200 For HBV F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPal9LUy1HeW9DRzd6dHVrMTVvTWFCaE5yN2JSaEtNWlFISG5RbDdhSmV3SXRsdDBhV0dBQzFOb05xdEFJaFFNVG5fUms5OTg2YkQ2cUF1VHV2TkFrdTFOSWdqQldNTGRaVGZSUksydWwtOVNubGJYSExQY2JZR192Q3RDNGZBdzg5eVZrTTBtcjhQeEUtbHplamtHeDM1ZEFkblRTSFc5TWNMTmpV?oc=5","date":"2024-06-06","type":"pipeline","source":"The Business Journals","summary":"Two Philadelphia-area biotech firms report progress on pursuit of a hepatitis B cure - The Business Journals","headline":"Two Philadelphia-area biotech firms report progress on pursuit of a hepatitis B cure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9MTlRNdTZWMlVKVmlxSE9ybkVLb0J0Uk9ZamEtbGVibUdBVWtXSjZIWVdLYU0xX1ZydHhaUE5LX19qdFoxRnl4bmJYLWJ0TEtVa3BuTFJQdXQ0MUU5RVg3Wi1pTXB6ODJpM0NIZkdESlFSWjRnVUhNXy01dTY?oc=5","date":"2024-03-28","type":"trial","source":"Clinical Trials Arena","summary":"Virion reports safety data from Phase IB HBV immunotherapy trial - Clinical Trials Arena","headline":"Virion reports safety data from Phase IB HBV immunotherapy trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-26","type":"deal","source":"PR Newswire","summary":"Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infect","headline":"Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQUGtEMms0VFhTVlhmRjAxRTRJSVZua1hUVUcxdEMwaVgxSFh3bXlvNUlvRTBUdjZ1aTJVSUtOdEktcm1jT0lZNDgtVGlBcGxDZTdpSTMzb0RNWF8tNmFIU1M3LTVjX1hhOGtrYmdzeU9HcVdPbm5oN3o1MHFRLTNISDVJQy1yMU1HOTJDSHJSdTdGQnhLTTV1U2hfOW00aGk4dWoteHlPbUlHVUtVRkNoWDVEdXJ4R2pSM2Nqbg?oc=5","date":"2023-10-26","type":"trial","source":"Clinical Trials Arena","summary":"Virion Therapeutics doses first patients in chronic Hepatitis B Phase Ib trial - Clinical Trials Arena","headline":"Virion Therapeutics doses first patients in chronic Hepatitis B Phase Ib trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-12","type":"trial","source":"PR Newswire","summary":"Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease a","headline":"Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPdENIM3pGLTVxVm5VZjVxSkFDdVZOWmU0cW5HREtzU3ZmejI4SnFQNGNlRnE2Z3FyTlo0ejlZY1BGeGpKWnhJZFhWakdlenkwb3hsajA1WC1kWlFuRTNHSnNqNlFTTW4ybkxoX2wtaDc4M25mRXJfMmk1bUszSVN4TXZOZnl2R0U0QXhYSzd3dTdfRXhFV2c?oc=5","date":"2021-07-12","type":"pipeline","source":"Yahoo Finance","summary":"Virion Therapeutics, LLC Announces the Appointment of M. Michelle Berrey, M.D., M.P.H. and Williamson Bradford, M.D., Ph.D. to Its Board of Directors - Yahoo Finance","headline":"Virion Therapeutics, LLC Announces the Appointment of M. Michelle Berrey, M.D., M.P.H. and Williamson Bradford, M.D., Ph","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}